drugset / Trial / NCT00664482
A Single-Patient Study Using AGS 006
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
Timeline
- Start
- 2007-05
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGS-006 | Unknown | — | — |